1. Articles in category: Drug Development

    1-24 of 71 1 2 3 »
    1. A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      Mol Cancer Ther. 2018 Apr 25;:

      Authors: Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L

      Read Full Article
    2. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

      Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

      Biomed Res Int. 2018;2018:1812535

      Authors: Vanichapol T, Chutipongtanate S, Anurathapan U, Hongeng S

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in childhood with 5-year survival rate of 40% in high-risk patients despite intensive therapies.

      Read Full Article
      Mentions: Immunotherapy
    3. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

      Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

      Future Oncol. 2018 Mar 29;:

      Authors: Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J

      Read Full Article
      Mentions: Refractory
    4. Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.

      Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.

      Biochem Biophys Res Commun. 2018 Mar 20;:

      Authors: Xu DQ, Toyoda H, Qi L, Morimoto M, Hanaki R, Iwamoto S, Komada Y, Hirayama M

      Abstract Mammalian target of rapamycin (mTOR) complex (mTORC) is frequently activated in diverse cancers. Although dual mTORC1/2 inhibitors are currently under development to treat various malignancies, the emergence of drug resistance has proven to be a major complication.

      Read Full Article
    5. Combination therapy in neuroblastoma: It`s all about the mix

      The combination of two cell division inhibitors causes malignant nervous system tumors to die off, as scientists from the “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) have shown in experimental studies.The combination strategy could be the key to new targeted therapies against this aggressive type of tumor. The Hopp Children’s Cancer Center at […]

      The post Combination therapy in neuroblastoma: It`s all about the mix appeared first on Healthcanal.com.

      Read Full Article
      Mentions: ALK
    6. The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease.

      The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease.

      Oncotarget. 2018 Feb 02;9(9):8334-8349

      Authors: De Wilde B, Beckers A, Lindner S, Kristina A, De Preter K, Depuydt P, Mestdagh P, Sante T, Lefever S, Hertwig F, Peng Z, Shi LM, Lee S, Vandermarliere E, Martens L, Menten B, Schramm A, Fischer M, Schulte J, Vandesompele J, Speleman F

      Read Full Article
      Mentions: ALK MYCN
    7. A molecular map of childhood cancers

      A molecular map of childhood cancers

      Researchers led by Professor Stefan Pfister from the “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) have been able to draw an extremely detailed molecular map of childhood cancers. In close collaboration with the German Cancer Consortium (DKTK) and the Society for Pediatric Oncology and Hematology (GPOH), they screened almost 1,000 tumor samples from […]

      The post A molecular map of childhood cancers appeared first on Healthcanal.com.

      Read Full Article
      Mentions: GPOH Genetics
    8. Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 26, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and other diseases, today announced that it received notification on Friday, February 23, 2018 that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to taurolidine for the treatment of neuroblastoma. Taurolidine is currently in preclinical development for neuroblastoma and is a key component in the Company's lead product, Neutrolin®, a novel anti-infective ...

      Read Full Article
      Mentions: Treatment
    9. CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Neuroblastoma is a severe form of cancer that originates in certain types of nerve tissues and most often begins in the adrenal glands, which are the small glands on top of the kidneys. It can develop in the chest, stomach, neck, pelvis, or bones. Children ages five or younger are most commonly affected ...

      Read Full Article
      Mentions: Treatment
    10. Molecular mechanisms and therapeutic targets in neuroblastoma.

      Molecular mechanisms and therapeutic targets in neuroblastoma.

      Pharmacol Res. 2018 Feb 18;:

      Authors: Johnsen JI, Dyberg C, Fransson S, Wickström M

      Abstract Neuroblastoma is the most common extracranical tumor of childhood and the most deadly tumor of infancy. It is characterized by early age onset and high frequencies of metastatic disease but also the capacity to spontaneously regress.

      Read Full Article
    11. Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment.

      Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment.

      J Pediatr Surg. 2018 Jan 31;:

      Authors: Frommann K, Appl B, Hundsdoerfer P, Reinshagen K, Eschenburg G

      Abstract PURPOSE: In spite of good initial therapy response neuroblastomas often spread to distant organs or relapse after periods of remission.

      Read Full Article
      Mentions: Treatment Relapse
    12. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.

      MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.

      Cell Death Dis. 2018 Feb 14;9(2):220

      Authors: Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R

      Abstract Heightened aerobic glycolysis and glutaminolysis are characteristic metabolic phenotypes in cancer cells.

      Read Full Article
      Mentions: MYCN
    13. A physiologically relevant 3D collagen-based scaffold - neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models.

      A physiologically relevant 3D collagen-based scaffold - neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models.

      Acta Biomater. 2018 Feb 12;:

      Authors: Curtin C, Nolan JC, Conlon R, Deneweth L, Gallagher C, Tan YJ, Cavanagh BL, Asraf AZ, Harvey H, Miller-Delaney S, Shohet J, Bray I, O'Brien FJ, Stallings RL, Piskareva O

      Read Full Article
    14. Origin and initiation mechanisms of neuroblastoma.

      Origin and initiation mechanisms of neuroblastoma.

      Cell Tissue Res. 2018 Feb 14;:

      Authors: Tsubota S, Kadomatsu K

      Abstract Neuroblastoma is an embryonal malignancy that affects normal development of the adrenal medulla and paravertebral sympathetic ganglia in early childhood. Extensive studies have revealed the molecular characteristics of human neuroblastomas, including abnormalities at genome, epigenome and transcriptome levels.

      Read Full Article
    15. MELK is a novel therapeutic target in high-risk neuroblastoma.

      MELK is a novel therapeutic target in high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2591-2602

      Authors: Guan S, Lu J, Zhao Y, Yu Y, Li H, Chen Z, Shi Z, Liang H, Wang M, Guo K, Chen X, Sun W, Bieerkehazhi S, Xu X, Sun S, Agarwal S, Yang J

      Abstract Maternal embryonic leucine zipper kinase (MELK) is known to modulate intracellular signaling and control cellular processes. However, the role of MELK in oncogenesis is not well defined.

      Read Full Article
      Mentions: MYCN
    16. The ALK receptor in sympathetic neuron development and neuroblastoma.

      The ALK receptor in sympathetic neuron development and neuroblastoma.

      Cell Tissue Res. 2018 Jan 27;:

      Authors: Janoueix-Lerosey I, Lopez-Delisle L, Delattre O, Rohrer H

      Abstract The ALK gene encodes a tyrosine kinase receptor characterized by an expression pattern mainly restricted to the developing central and peripheral nervous systems.

      Read Full Article
      Mentions: ALK
    17. 'Hijacker' drives cancer in some patients with high-risk neuroblastoma

      Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including ...

      Read Full Article
    18. Epigenetic regulation of neuroblastoma development.

      Epigenetic regulation of neuroblastoma development.

      Cell Tissue Res. 2018 Jan 19;:

      Authors: Kaat D, Frank S

      Abstract In recent years, technological advances have enabled a detailed landscaping of the epigenome and the mechanisms of epigenetic regulation that drive normal cell function, development and cancer.

      Read Full Article
    19. MiRNA Influences in Neuroblast Modulation: An Introspective Analysis.

      MiRNA Influences in Neuroblast Modulation: An Introspective Analysis.

      Genes (Basel). 2018 Jan 09;9(1):

      Authors: Zammit V, Baron B, Ayers D

      Abstract Neuroblastoma (NB) is the most common occurring solid paediatric cancer in children under the age of five years. Whether of familial or sporadic origin, chromosome abnormalities contribute to the development of NB and cause dysregulation of microRNAs (miRNAs).

      Read Full Article
    20. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.

      Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.

      Biochem J. 2018 Jan 02;:

      Authors: Schultz CR, Geerts D, Mooney M, El-Khawaja R, Koster J, Bachmann AS

      Abstract The eukaryotic initiation factor 5A (eIF5A), which contributes to several crucial processes during protein translation, is the only protein that requires activation by a unique post-translational hypusine modification.

      Read Full Article
      Mentions: DFMO
    21. mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      ACS Appl Mater Interfaces. 2018 Jan 03;:

      Authors: Haimov E, Weitman H, Polani S, Schori H, Zitoun D, Shefi O

      Abstract Photodynamic Therapy (PDT) is a promising therapeutic modality for cancer. However, current protocols using bare drugs suffer from several limitations that impede its beneficial clinical effects. Here, we introduce a new approach for an efficient PDT treatment.

      Read Full Article
    1-24 of 71 1 2 3 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) Immunotherapy
    2. (1 articles) PD-1